Chronic B-Cell Leukemia (CBCL)
Symptoms, Doctors, Treatments, Advances & More

Chronic B-Cell Leukemia (CBCL) Overview

Save information for later
Sign Up

Learn About Chronic B-Cell Leukemia (CBCL)

View Main Condition: Leukemia

What is the definition of Chronic B-Cell Leukemia (CBCL)?
Chronic B cell leukemia is a type of chronic lymphocytic leukemia (CLL), or cancer of the blood and bone marrow that mainly affects adults. In chronic B cell leukemia, the bone marrow produces too many B lymphocytes, which are white blood cells that fight infection. Chronic B cell leukemia represents 95% of all chronic lymphocytic leukemias.
What are the symptoms of Chronic B-Cell Leukemia (CBCL)?
Individuals with early chronic B cell leukemia may not have any symptoms. Symptoms of intermediate and advanced stage chronic B cell leukemia may include painless, enlarged lymph nodes; fatigue; fever; pain in the upper left region of the abdomen; enlarged spleen; easy bruising or bleeding; pinpoint, dark red spots under the skin (petechiae); night sweats; weight loss; and frequent infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chronic B-Cell Leukemia (CBCL)?
Treatment for chronic B cell leukemia depends on the stage. Early stage chronic B cell leukemia may not need treatment and may involve watchful waiting. Treatment for intermediate and advanced stages chronic B cell leukemia may include targeted therapy, chemotherapy, radiation therapy, immunotherapy, and bone marrow or peripheral stem cell transplant.
Who are the top Chronic B-Cell Leukemia (CBCL) Local Doctors?
Stephen J. Schuster
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Stephen J. Schuster
Hematology
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Stephen J. Schuster
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Schuster is a Hematologist in Philadelphia, Pennsylvania. Dr. Schuster is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Nilanjan Ghosh
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Nilanjan Ghosh
Hematology | Oncology
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Nilanjan Ghosh
Hematology | Oncology

Atrium Health Levine Cancer Institute (Hematology)

1021 Morehead Medical Drive, Building 2, Suite 60201, 
Charlotte, NC 
980-442-4363
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nilanjan Ghosh is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Ghosh is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Chronic B-Cell Leukemia (CBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ghosh is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Jon E. Arnason
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Jon E. Arnason
Internal Medicine
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Jon E. Arnason
Internal Medicine

Beth Israel Deaconess Medical Center - Hematology/Oncology

330 Brookline Avenue, Shapiro 7, 
Boston, MA 
617-667-9920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jon Arnason is an Internal Medicine provider in Boston, Massachusetts. Dr. Arnason is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant.

View All Doctors
What are the latest Chronic B-Cell Leukemia (CBCL) Clinical Trials?
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Who is this study for: Adult patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Biological
Study Drugs: Lisocabtagene Maraleucel, Ibrutinib
Study Phase: Phase 1/Phase 2

Summary: This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy trea...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological
Study Phase: Phase 3

Summary: The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) cr...

View All Clinical Trials